Skip to main content
SpringerLink
Log in

Brintellix and Brilinta prescribing errors

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • FDA. FDA Drug Safety Communication: FDA warns about prescribing and dispensing errors resulting from brand name confusion with antidepressant Brintellix (vortioxetine) and antiplatelet Brilinta (ticagrelor). Internet Document : 30 Jul 2015. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm456341.htm

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brintellix and Brilinta prescribing errors. Reactions Weekly 1564, 1 (2015). https://doi.org/10.1007/s40278-015-4144-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-015-4144-3

Search

Navigation